Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNY – Research Report), Galapagos (GLPG – Research Report) and Emergent Biosolutions (EBS – Research Report).
Alnylam Pharma (ALNY)
In a report released today, Luca Issi from RBC Capital reiterated a Buy rating on Alnylam Pharma, with a price target of $275.00. The company’s shares closed last Wednesday at $185.84.
According to TipRanks.com, Issi is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Alnylam Pharma has an analyst consensus of Moderate Buy, with a price target consensus of $251.27, which is a 34.8% upside from current levels. In a report issued on May 16, BMO Capital also maintained a Buy rating on the stock with a $250.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Galapagos (GLPG)
In a report released today, James Gordon from J.P. Morgan maintained a Hold rating on Galapagos, with a price target of $45.00. The company’s shares closed last Wednesday at $41.24.
According to TipRanks.com, Gordon is ranked #3657 out of 8379 analysts.
Currently, the analyst consensus on Galapagos is a Hold with an average price target of $49.25, implying a 19.1% upside from current levels. In a report issued on May 18, Morgan Stanley also maintained a Hold rating on the stock with a $42.00 price target.
Emergent Biosolutions (EBS)
In a report released today, Robert Wasserman from Benchmark Co. reiterated a Buy rating on Emergent Biosolutions, with a price target of $22.00. The company’s shares closed last Wednesday at $8.29, close to its 52-week low of $7.74.
According to TipRanks.com, Wasserman is a 1-star analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Emergent Biosolutions with a $15.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ALNY:
